关于高血压心力衰竭患者的C-反应蛋白水平和预后的维里西瓜特
Yabing Cao1, Yunjing Sun2, Bo Miao3
1Department 1 of Cardiology, Xingtai Third Hospital, Xingtai, Hebei Province, 054000, China.
概括
韦里西瓜特有效地改善高血压心力衰竭 (HHF) 患者的心脏功能,与安慰剂相比显示出显著的好处. 高C反应蛋白 (CRP) 水平表明HHF的预后不佳.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 高血压性心力衰竭 (HHF) 是一个重大的临床挑战,因为它的发病率很高,患者的治疗结果不佳.
- 对HHF有效的治疗策略仍然是积极研究和临床需求的领域.
研究的目的:
- 评估Vericiguat在被诊断为高血压心力衰竭 (HHF) 的患者中的疗效和安全性.
- 调查C-反应蛋白 (CRP) 水平与高高压患者的预后之间的相关性.
主要方法:
- 一项涉及110名HHF患者的研究随机分为安慰剂和Vericiguat组.
- 通过心声学和6分钟步行测试 (6MWT) 评估心脏功能.
- 测量了包括NT-proBNP,cTnI,ET-1,NO和CRP在内的生物标志物.
主要成果:
- 维里西瓜特治疗导致心脏功能改善,由减少LVESD/LVEDD,增加LVEF和增强6MWT性能证明.
- 在Vericiguat组中观察到NT-proBNP,cTnI,ET-1,NO和CRP水平的显著改善.
- 维瑞西瓜特组的总有效率 (92.7%) 与安慰剂 (76.4%) 相比较高,并具有可比的不良事件率.
- 基线CRP水平升高与患病预后不佳且心脏功能没有改善的患者比例较高有关,CRP被确定为独立的风险因素.
结论:
- 韦里西瓜特在改善患有高血压心力衰竭 (HHF) 的患者的心脏功能方面显示出安全性和有效性.
- 基线C反应蛋白 (CRP) 水平作为预测HHF患者预后的关键指标.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
68
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
68
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
625
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
625
01:22Heart Failure Drugs: β-Blockers
324
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
324
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:25Antihypertensive Drugs: Direct Renin Inhibitors
512
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
512